Document is current
Any future updates will be listed below
-
Authors
Madlener, Sibylle
Stepien, Natalia
Senfter, Daniel
Mayr, Lisa
Laemmerer, Anna
Hedrich, Cora
Baumgartner, Alicia
Lötsch-Gojo, Daniela
Sterba, Jaroslav
Pokorna, Petra
Kiesel, Barbara
Widhalm, Georg
Eckert, Franziska
Preusser, Matthias
Rössler, Karl
Azizi, Amedeo
Peyrl, Andreas
Czech, Thomas
Haberler, Christine
Slavc, Irene
Kasprian, Gregor
Dorfer, Christian
Furtner, Julia
Gojo, Johannes
-
Funding
Funding for this research was provided by:
Oncomine Clinical Research Grant
City of Vienna Fund for innovative interdisciplinary Cancer Research (21080)
Physician Researcher Pathway Scholarships of the Medical University of Vienna
Austrian Science Fund (J4353-B28)
Verein unser_kind
Forschungsgesellschaft für Cerebrale Tumore
Medical University of Vienna
- License Information
-
More Information
Article History
Received: 7 October 2024
Revised: 11 December 2024
Accepted: 23 December 2024
First Online: 3 January 2025
Declarations
:
: MP has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp and Dome, Tocagen, Adastra, Gan & Lee Pharmaceuticals, Janssen, Servier, Miltenyi, Böhringer-Ingelheim, Telix, Medscape, OncLive. All the other authors declare no conflicts of interests. JG has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Novartis, Roche. A.A. has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Novartis, Alexion. All the other authors declare no conflicts of interests.
: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of the Medical University of Vienna (EK 1244/2016).
